According to the World Health Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 – 30,000 deaths occur worldwide annually due to the leishmaniasis. There are three types of leishmaniasis namely mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis. Visceral leishmaniasis (VL) is the most serious condition among the other two forms of leishmaniasis. According to the World Health Organization (WHO), about 50,000 to 90,000 new cases of visceral leishmaniasis occur worldwide annually. According to the WHO, in 2015, more than 90% of the new cases of visceral leishmaniasis were from Kenya, Somalia, Ethiopia, India, Brazil, Sudan, and South Sudan creating higher opportunity for leishmaniasis treatment market. The prevalence of cutaneous leishmaniasis in the North and South America, the Middle East, Central Asia, and Mediterranean basin is approximately 95%, according to the WHO April 2017 factsheet. People with leishmaniasis infection develop several symptoms, such as fever, weight loss, sores on skin, nose, mouth or throat, enlargement of spleen and liver, and abnormal blood tests. Some patients show symptoms of anemia, leukopenia, and thrombocytopenia. Geriatric population, infants, pregnant or lactating women, and HIV infected people have a high risk of acquiring leishmaniasis infections, due to their weak immune systems.
Leishmaniasis, also known as Lassa fever is an infectious disease of the lymphatic system which results from infection with Leishmaniasis parasites. It is spread to humans by the bite of leishmaniasis-carried sand flies, which are prevalent in regions of the western Pacific, central Asia, South Africa, India, and Sri Lanka. These parasites are transmitted through insect bites, blood transfusions, and infected rashes.The recent estimates indicate that there are approximately twenty-four million new cases of leishmaniasis every year in the United States alone, primarily in the middle east and Southeast Asia. Leishmaniasis has been considered one of the most neglected tropical diseases, with less than one percent of doctors practicing dermatologic surgery. Because of this, leishmaniasis has not been included on the lists of curable tropical diseases, and the only way to prevent serious health problems is to prevent contact with infected animals or their waste.
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/932
Leishmaniasis Treatment Market Taxonomy:
On the basis of disease type, the leishmaniasis treatment market is segmented into:
- Cutaneous leishmaniasis
- Visceral leishmaniasis
- Mucocutaneous leishmaniasis
On the basis of drug type, the leishmaniasis treatment market is segmented into:
- Pentavalent antimonials
- Sodium stibogluconate
- SSG Meglumine antimoniate
- Amphotericin B
- Liposomal amphotericin B
Advent of new chemical entity is driving leishmaniasis treatment market growth
Advancement in the drug discovery is expected to foster growth of the leishmaniasis treatment market. According to data published in 2017, by Drugs for Neglected Diseases initiative (DNDi’), two new chemical entities (NCE) DNDI-6148 and DNDI-0690 are introduced into the preclinical development stage to treat visceral and cutaneous leishmaniasis in 2016. Immunomodulator- CpG-D35, is also in pre-clinical development stage, which will be used as an adjunct along with drug therapy to fight cutaneous leishmaniasis.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/932
Agreement between WHO and Gilead Sciences, Inc. to escalate leishmaniasis treatment market
In 2016, the World Health Organization (WHO) and Gilead Sciences, Inc. signed an agreement to donate 3, 80,400 vials of AmBisome (liposomal amphotericin B), extending their previous agreement from 2016 to 2021. The five year collaboration and funding of US$ 20 million by Gilead Sciences, Inc. are intended to provide access to diagnosis and treatment to the populations affected by visceral leishmaniasis in key endemic countries such as Ethiopia, India, Nepal, Bangladesh, South Sudan, and Sudan. Financial contribution made by Gilead Sciences, Inc. helped WHO to expand, control, and reinforce surveillance in many endemic countries.
Key Players in the Leishmaniasis treatment market
Key players enagged in the leishmaniasis treatment market include Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, and Lifecare Innovations Private Limited.
Reasons to Purchase this Report
• Current and future of global Leishmaniasis Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
To Direct Purchase of this Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/932
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Leishmaniasis Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Leishmaniasis Treatment Industry Impact
Chapter 2 Global Leishmaniasis Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Leishmaniasis Treatment (Volume and Value) by Type
2.3 Global Leishmaniasis Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Leishmaniasis Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Leishmaniasis Treatment Market Analysis
Chapter 6 East Asia Leishmaniasis Treatment Market Analysis
Chapter 7 Europe Leishmaniasis Treatment Market Analysis
Chapter 8 South Asia Leishmaniasis Treatment Market Analysis
Chapter 9 Southeast Asia Leishmaniasis Treatment Market Analysis
Chapter 10 Middle East Leishmaniasis Treatment Market Analysis
Chapter 11 Africa Leishmaniasis Treatment Market Analysis
Chapter 12 Oceania Leishmaniasis Treatment Market Analysis
Chapter 13 South America Leishmaniasis Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Leishmaniasis Treatment Business
Chapter 15 Global Leishmaniasis Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027